These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
441 related articles for article (PubMed ID: 25340798)
1. Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. Kauwe JS; Bailey MH; Ridge PG; Perry R; Wadsworth ME; Hoyt KL; Staley LA; Karch CM; Harari O; Cruchaga C; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; ; Fagan AM; Holtzman DM; Morris JC; Goate AM PLoS Genet; 2014 Oct; 10(10):e1004758. PubMed ID: 25340798 [TBL] [Abstract][Full Text] [Related]
2. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study. Han MR; Schellenberg GD; Wang LS; BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310 [TBL] [Abstract][Full Text] [Related]
3. Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages. Chung J; Wang X; Maruyama T; Ma Y; Zhang X; Mez J; Sherva R; Takeyama H; ; Lunetta KL; Farrer LA; Jun GR Alzheimers Dement; 2018 May; 14(5):623-633. PubMed ID: 29274321 [TBL] [Abstract][Full Text] [Related]
4. Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort. Cong W; Meng X; Li J; Zhang Q; Chen F; Liu W; Wang Y; Cheng S; Yao X; Yan J; Kim S; Saykin AJ; Liang H; Shen L; BMC Genomics; 2017 May; 18(1):421. PubMed ID: 28558704 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related]
6. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Kim S; Swaminathan S; Shen L; Risacher SL; Nho K; Foroud T; Shaw LM; Trojanowski JQ; Potkin SG; Huentelman MJ; Craig DW; DeChairo BM; Aisen PS; Petersen RC; Weiner MW; Saykin AJ; Neurology; 2011 Jan; 76(1):69-79. PubMed ID: 21123754 [TBL] [Abstract][Full Text] [Related]
7. Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. Deming Y; Li Z; Kapoor M; Harari O; Del-Aguila JL; Black K; Carrell D; Cai Y; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Huang KL; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Kim S; Saykin AJ; De Jager PL; Albert M; Moghekar A; O'Brien R; Riemenschneider M; Petersen RC; Blennow K; Zetterberg H; Minthon L; Van Deerlin VM; Lee VM; Shaw LM; Trojanowski JQ; Schellenberg G; Haines JL; Mayeux R; Pericak-Vance MA; Farrer LA; Peskind ER; Li G; Di Narzo AF; ; ; Kauwe JS; Goate AM; Cruchaga C Acta Neuropathol; 2017 May; 133(5):839-856. PubMed ID: 28247064 [TBL] [Abstract][Full Text] [Related]
8. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. Cruchaga C; Kauwe JS; Mayo K; Spiegel N; Bertelsen S; Nowotny P; Shah AR; Abraham R; Hollingworth P; Harold D; Owen MM; Williams J; Lovestone S; Peskind ER; Li G; Leverenz JB; Galasko D; ; Morris JC; Fagan AM; Holtzman DM; Goate AM PLoS Genet; 2010 Sep; 6(9):e1001101. PubMed ID: 20862329 [TBL] [Abstract][Full Text] [Related]
9. Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels. Maxwell TJ; Corcoran C; Del-Aguila JL; Budde JP; Deming Y; Cruchaga C; Goate AM; Kauwe JSK; Alzheimers Res Ther; 2018 Aug; 10(1):86. PubMed ID: 30153862 [TBL] [Abstract][Full Text] [Related]
10. Amyloid, tau and risk of Alzheimer's disease: a Mendelian randomization study. Yeung CHC; Lau KWD; Au Yeung SL; Schooling CM Eur J Epidemiol; 2021 Jan; 36(1):81-88. PubMed ID: 32929646 [TBL] [Abstract][Full Text] [Related]
11. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Harari O; Cruchaga C; Kauwe JS; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Goate AM; Biol Psychiatry; 2014 May; 75(9):723-31. PubMed ID: 24548642 [TBL] [Abstract][Full Text] [Related]
12. Genome-wide association and interaction studies of CSF T-tau/Aβ Li J; Zhang Q; Chen F; Meng X; Liu W; Chen D; Yan J; Kim S; Wang L; Feng W; Saykin AJ; Liang H; Shen L; Neurobiol Aging; 2017 Sep; 57():247.e1-247.e8. PubMed ID: 28641921 [TBL] [Abstract][Full Text] [Related]
13. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort. Elias-Sonnenschein LS; Helisalmi S; Natunen T; Hall A; Paajanen T; Herukka SK; Laitinen M; Remes AM; Koivisto AM; Mattila KM; Lehtimäki T; Verhey FR; Visser PJ; Soininen H; Hiltunen M PLoS One; 2013; 8(4):e59676. PubMed ID: 23573206 [TBL] [Abstract][Full Text] [Related]
14. Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects. Zhang W; Young JI; Gomez L; Schmidt MA; Lukacsovich D; Varma A; Chen XS; Martin ER; Wang L Alzheimers Res Ther; 2023 Apr; 15(1):78. PubMed ID: 37038196 [TBL] [Abstract][Full Text] [Related]
15. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease. Kimura A; Yoshikura N; Hayashi Y; Inuzuka T J Alzheimers Dis; 2018; 61(2):581-588. PubMed ID: 29171996 [TBL] [Abstract][Full Text] [Related]
17. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C; Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532 [TBL] [Abstract][Full Text] [Related]